


## Key figures 2016



As part of the preparations for the IPO which took place on 7 April 2017, Galenica restated the financials from 2014 as if Galenica had been a standalone entity (combined financial statements 2014–2016).

in million CHF	2016	2015	Change
Net sales <sup>1)</sup>	3,008.9	2,914.9	+3.2%
Health & Beauty	1,437.0	1,393.3	+3.1%
Services	2,328.9	2,244.5	+3.8%
EBITDA adjusted <sup>1)2)</sup>	176.0	166.9	+5.4%
in % of net sales	5.9%	5.7%	
EBITDA <sup>1)</sup>	165.6	159.8	+3.7%
Health & Beauty	116.0	112.0	+3.6%
Services	60.1	55.5	+8.4%
EBIT adjusted <sup>1)2)</sup> in % of net sales	134.2 4.5%	125.7 4.3%	+6.8%
EBIT <sup>1)</sup>	123.8	118.5	+4.5%
Health & Beauty	93.5	88.6	+5.6%
Services	39.9	36.2	+10.3%
Net profit	83.4	81.1	+2.8%
Attributable to shareholders of Galenica Ltd.	83.4	81.1	+2.8%
Share of minority interests	-	-	
Net profit adjusted <sup>2)</sup>	92.1	87.3	+5.5%
Investment in property, plant and equipment and intangible assets	35.0	43.9	-20.1%
Cash flow from operating activities	156.8	132.4	+18.4%
Free cash flow <sup>3)</sup>	92.5	76.6	+20.7%

<sup>1)</sup> Key figures are reported for each Segment not taking into account Corporate and eliminations

<sup>2)</sup> Excluding the effects of IAS 19

<sup>3)</sup> Calculated as cash flow from operating activities - cash flow from investing activities

in million CHF	
Total assets (pro-forma balance sheet as at 1 January 2017) <sup>4)</sup>	1,658.6
Shareholders' equity (pro-forma balance sheet as at 1 January 2017) <sup>4)</sup>	745.3
Equity ratio (pro-forma balance sheet as at 1 January 2017) <sup>4)</sup>	44.9%
Capital contribution reserve (pro-forma balance sheet as at 1 January 2017) <sup>4)</sup>	560.9
Net debt (pro-forma balance sheet as at 1 January 2017) <sup>4)</sup>	350.3
Net debt/EBITDA adjusted <sup>2)</sup>	2.0
Gearing	47.0%

	2016	2015	Change
Own pharmacies and shareholdings	329	318	+11
of which fully consolidated	258	252	+6
of which consolidated at equity (joint venture and minority holdings)	71	66	+5
Independent partners	167	173	-6
Total pharmacy network	496	491	+5

Further information on the financial track-record of Galenica can be found in the annual report 2016 of the Galenica Group at www.galenica.com, under the heading "Publications", and in the investor presentation under the heading "Investors".

## Share information

Since 7 April 2017, Galenica shares have been listed on the SIX Swiss Exchange under the ticker symbol GALE.

	SIX Swiss Exchange	
Listing	(International Reporting Standard)	
Ticker symbol	GALE	
Swiss security number	36 067 446	
ISIN	CH036 067 446 6	
Total number of ordinary registered shares	50,000,000	
Nominal value	CHF 0.10 per registered share	
Price on first trading day (7 April 2017)	CHF 43.00	
Market capitalisation on first trading day (7 April 2017)	CHF 2,150 million	
Earnings per share	CHF 1.67	
Earnings per share adjusted <sup>2)</sup>	CHF 1.84	
Shareholders' equity per share	CHF 14.91	
Adjusted price/earnings ratio <sup>2)</sup>		
on first trading day (7 April 2017)	23.4	

<sup>2)</sup> Excluding the effects of IAS 19

<sup>&</sup>lt;sup>4)</sup> Galenica Ltd. (previously Galenica Santé Ltd.) was incorporated on 13 February 2017, with a share capital of CHF 5.0 million and capital contribution reserves of CHF 560.9 million, which contribution was effective as of 1 January 2017. In addition, Vifor Pharma Ltd. provided a loan of CHF 360.0 million, which was also effective as of 1 January 2017.